Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report released on Sunday. The firm issued a hold rating on the medical research company’s stock.

Several other equities analysts have also recently commented on the company. B. Riley reaffirmed a buy rating and issued a $3.00 price target on shares of Cytosorbents in a report on Wednesday, May 15th. HC Wainwright restated a neutral rating and issued a $1.00 target price on shares of Cytosorbents in a research note on Tuesday, May 7th.

Cytosorbents Stock Performance

CTSO opened at $1.01 on Friday. The company has a quick ratio of 1.21, a current ratio of 1.49 and a debt-to-equity ratio of 0.10. The stock’s 50 day moving average price is $0.90 and its two-hundred day moving average price is $0.93. The firm has a market capitalization of $54.85 million, a P/E ratio of -1.71 and a beta of 0.57. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $3.85.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). Cytosorbents had a negative net margin of 75.07% and a negative return on equity of 129.89%. The business had revenue of $9.79 million for the quarter, compared to the consensus estimate of $9.78 million. During the same quarter last year, the company posted ($0.17) earnings per share. On average, equities analysts forecast that Cytosorbents will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Cytosorbents

A number of institutional investors have recently added to or reduced their stakes in the stock. Key Client Fiduciary Advisors LLC raised its holdings in shares of Cytosorbents by 188.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after buying an additional 22,557 shares in the last quarter. Raymond James & Associates bought a new position in shares of Cytosorbents during the fourth quarter valued at $56,000. CM Management LLC boosted its stake in shares of Cytosorbents by 98.8% in the 1st quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock valued at $784,000 after purchasing an additional 410,000 shares in the last quarter. Sargent Investment Group LLC boosted its stake in shares of Cytosorbents by 4.1% in the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after purchasing an additional 51,699 shares in the last quarter. Finally, Neuberger Berman Group LLC grew its holdings in shares of Cytosorbents by 19.9% in the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after purchasing an additional 299,103 shares during the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.